表紙:世界のファーマコビジランス市場:臨床試験段階、方法、サービスプロバイダー、プロセスフロー、治療分野、エンドユーザー、地域別 - 予測と機会(2026年)
市場調査レポート
商品コード
1033261

世界のファーマコビジランス市場:臨床試験段階、方法、サービスプロバイダー、プロセスフロー、治療分野、エンドユーザー、地域別 - 予測と機会(2026年)

Global Pharmacovigilance Market, By Clinical Trial Phase, By Method, By Service Provider, By Process Flow, By Therapeutic Area, By End-User, By Region, Forecast & Opportunities, 2026

出版日: | 発行: TechSci Research | ページ情報: 英文 111 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.11円

こちらのレポートには、数時間(ご購入金額の10%)分のアナリストへの質問/追加調査サービスが含まれております。

世界のファーマコビジランス市場:臨床試験段階、方法、サービスプロバイダー、プロセスフロー、治療分野、エンドユーザー、地域別 - 予測と機会(2026年)
出版日: 2021年10月01日
発行: TechSci Research
ページ情報: 英文 111 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

世界のファーマコビジランス市場は、世界の医薬品消費量の増加と医薬品開発の進展を背景に、予測期間中に2桁のCAGRを記録する見通しです。がんや糖尿病などの慢性疾患の増加に伴い、先進的で効果的な医薬品の必要性が高まっています。医薬品の有害事象(ADR)の可能性を考慮して、医療機関はファーマコビジランスサービスを継続的に導入しています。さらに、様々な地域で消費者保護法が制定されたことも、当市場の成長を後押ししています。

当レポートでは、世界のファーマコビジランス市場を調査し、製品の概要、新型コロナウイルス感染症(COVID-19)の市場への影響、セグメント(臨床試験段階、方法、サービスプロバイダー、プロセスフロー、治療分野、エンドユーザー)別の市場規模および市場シェアの予測、主要地域・国別の詳細動向、市場成長の促進要因および課題、市場動向、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 製品の概要

第2章 調査手法

第3章 COVID-19の世界のファーマコビジランス市場への影響

第4章 エグゼクティブサマリー

第5章 顧客の声

第6章 世界のファーマコビジランス市場の見通し

  • 市場規模と予測
  • 市場シェアと予測
    • 臨床試験段階別(前臨床、第I相、第II相、第III相、第IV相)
    • 方法別(自発的報告、強化型有害事象(ADR)報告、標的自発的報告、コホートイベント監視、EHRマイニング)
    • サービスプロバイダー別(自社、契約アウトソーシング)
    • プロセスフロー別(事例データ管理、シグナル検出、リスク管理システム)
    • 治療分野別(腫瘍学、神経学、心臓病学、その他)
    • エンドユーザー別(製薬・バイオテクノロジー企業、医療機器メーカー、その他)
    • 企業別(2021年)
    • 地域別
  • 製品の市場マップ

第7章 アジア太平洋地域のファーマコビジランス市場の見通し

  • 市場規模と予測
  • 市場シェアと予測
    • 臨床試験段階別
    • 方法別
    • サービスプロバイダー別
    • プロセスフロー別
    • 治療分野別
    • エンドユーザー別
    • 国別
  • アジア太平洋地域:国別分析
    • 中国のファーマコビジランス市場の見通し
    • インドのファーマコビジランス市場の見通し
    • 日本のファーマコビジランス市場の見通し
    • 韓国のファーマコビジランス市場の見通し
    • オーストラリアのファーマコビジランス市場の見通し

第8章 欧州のファーマコビジランス市場の見通し

  • 市場規模と予測
  • 市場シェアと予測
    • 臨床試験段階別
    • 方法別
    • サービスプロバイダー別
    • プロセスフロー別
    • 治療分野別
    • エンドユーザー別
    • 国別
  • 欧州:国別分析
    • フランスのファーマコビジランス市場の見通し
    • ドイツのファーマコビジランス市場の見通し
    • 英国のファーマコビジランス市場の見通し
    • イタリアのファーマコビジランス市場の見通し
    • スペインのファーマコビジランス市場の見通し

第9章 北米のファーマコビジランス市場の見通し

  • 市場規模と予測
  • 市場シェアと予測
    • 臨床試験段階別
    • 方法別
    • サービスプロバイダー別
    • プロセスフロー別
    • 治療分野別
    • エンドユーザー別
    • 国別
  • 北米:国別分析
    • 米国のファーマコビジランス市場の見通し
    • メキシコのファーマコビジランス市場の見通し
    • カナダのファーマコビジランス市場の見通し

第10章 南米のファーマコビジランス市場の見通し

  • 市場規模と予測
  • 市場シェアと予測
    • 臨床試験段階別
    • 方法別
    • サービスプロバイダー別
    • プロセスフロー別
    • 治療分野別
    • エンドユーザー別
    • 国別
  • 南米:国別分析
    • ブラジルのファーマコビジランス市場の見通し
    • アルゼンチンのファーマコビジランス市場の見通し
    • コロンビアのファーマコビジランス市場の見通し

第11章 中東・アフリカのファーマコビジランス市場の見通し

  • 市場規模と予測
  • 市場シェアと予測
    • 臨床試験段階別
    • 方法別
    • サービスプロバイダー別
    • プロセスフロー別
    • 治療分野別
    • エンドユーザー別
    • 国別
  • 中東・アフリカ:国別分析
    • 南アフリカのファーマコビジランス市場の見通し
    • サウジアラビアのファーマコビジランス市場の見通し
    • アラブ首長国連邦のファーマコビジランス市場の見通し

第12章 市場力学

  • 促進要因
  • 課題

第13章 市場の動向と発展

第14章 競合情勢

  • 競合の見通し
  • 企業プロファイル
    • IBM Corporation
    • Accenture Plc
    • Linical Accelovance
    • Cognizant Technology Solutions Corporation
    • Laboratory Corporation of America Holdings
    • ArisGlobal LLC
    • ICON plc
    • Capgemini SE
    • Parexel International Corporation
    • Wipro Ltd
    • United BioSource Corporation
    • BioClinica Inc.
    • TAKE Solutions Ltd.
    • ITClinical
    • Foresight Group International AG

第15章 戦略的推奨事項

第16章 当社について&免責事項

目次
Product Code: 4809

Global pharmacovigilance market is anticipated to witness double digit CAGR during the forecast period owing to the increasing drug consumption and drug developments around the globe. Growing prevalence of chronic diseases such as oncology, diabetes, and others has created the need for advanced and more effective pharmaceutical drugs. Keeping in view the chances of Adverse Drug Reactions (ADR) and drug toxicity, healthcare companies are continuously incorporating pharmacovigilance services. Moreover, numerous consumer health protection acts across various regions are further propelling the growth of this market.

Pharmacovigilance is concerned with identifying the hazards associated with pharmaceutical products and minimizing the risk of any harm that may come to patients. The service helps in finding the new safety concerns and evaluating the already known risks. It also helps in keeping a watch on the benefit risk balance of a drug. Any change in the benefit risk ratio will alter the safety profile of the drug.

Global pharmacovigilance market can be segmented based on clinical trial phase, method, service provider, end-user and region. Based on service provider, the market is categorized into in-house and contract outsourcing. Among them, the contract outsourcing service provider dominated the market in 2020 and is expected to dominate the market during the forecast period owing to the fact that it eliminates the risk of business overhead costs and is thus, being increasingly adopted by healthcare companies

Regionally, Asia-Pacific dominates the market and is expected to undergo highest CAGR until 2026 owing to stringent healthcare regulations across the region. The region has also a large patient pool, which is leading to increasing number of clinical trials. Also, countries such as India and China have large clinical research spaces and offer attractive opportunities to healthcare companies.

Major companies operating in global pharmacovigilance market include IBM Corporation, Accenture Plc, Linical Accelovance, Cognizant Technology Solutions Corporation, Laboratory Corporation of America Holdings, ArisGlobal LLC, ICON plc, Capgemini SE, Parexel International Corporation, Wipro Ltd, United BioSource Corporation, BioClinica Inc., TAKE Solutions Ltd., ITClinical, Foresight Group International AG and others. The companies are focusing on research and development activities to offer better pharmacovigilance services and increase their global market share.

Years considered for this report:

Historical Years: 2016-2019

Base Year: 2020

Estimated Year: 2021

Forecast Period: 2022-2026

Objective of the Study:

  • To analyze and forecast the market size of global pharmacovigilance market.
  • To forecast global pharmacovigilance market based on clinical trial phase, method, service provider, end-user, company and regional distribution.
  • To identify drivers and challenges for global pharmacovigilance market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions etc. in global pharmacovigilance market.
  • To identify and analyze the profile of leading players operating in the global pharmacovigilance market.

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of service providers across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the service providers which could not be identified due to the limitations of secondary research.

TechSci Research calculated global pharmacovigilance market size using a bottom-up approach, where data for various end user industries and its application across various product types was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also used by TechSci Research.

Key Target Audience:

  • Pharmacovigilance service providers, pharmaceutical companies and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, industry associations, forums and alliances related to pharmacovigilance
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as pharmacovigilance companies, end users etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global pharmacovigilance market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Pharmacovigilance Market, By Clinical Trial Phase:

Pre-Clinical

Phase 1

Phase 2

Phase 3

Phase 4

  • Global Pharmacovigilance Market, By Method:

Spontaneous Reporting

Intensified ADR Reporting

Targeted Spontaneous Reporting

Cohort Event Monitoring

EHR Mining

  • Global Pharmacovigilance Market, By Service Provider:

In-House

Contract Outsourcing

  • Global Pharmacovigilance Market, By Process Flow :

Case Data Management

Signal Detection

Risk Management System

  • Global Pharmacovigilance Market, By Therapeutic Area

Oncology

Neurology

Cardiology

Others

  • Global Pharmacovigilance Market, By End-User:

Pharmaceutical & Biotechnology Companies

Medical Device Manufacturers

Others

  • Global Pharmacovigilance Market, By Region:

Asia-Pacific

  • China
  • Japan
  • India
  • South Korea
  • Australia

Europe

  • France
  • Germany
  • United Kingdom
  • Italy
  • Spain

North America

  • United States
  • Mexico
  • Canada

South America

  • Brazil
  • Argentina
  • Colombia

Middle East & Africa

  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global pharmacovigilance market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Profit Margin Analysis

  • Profit margin analysis in case of direct and indirect sales channel.

Table of Contents

1. Product Overview

2. Research Methodology

3. Impact of COVID-19 on Global Pharmacovigilance Market

4. Executive Summary

5. Voice of Customer

6. Global Pharmacovigilance Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Clinical Trial Phase (Pre-Clinical, Phase 1, Phase 2, Phase 3, and Phase 4)
    • 6.2.2. By Method (Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring, EHR Mining)
    • 6.2.3. By Service Provider (In-House, Contract Outsourcing)
    • 6.2.4. By Process Flow (Case Data Management, Signal Detection, Risk Management System)
    • 6.2.5. By Therapeutic Area (Oncology, Neurology, Cardiology, Others)
    • 6.2.6. By End-User (Pharmaceutical & Biotechnology Companies, Medical Device Manufacturers, Others)
    • 6.2.7. By Company (2021)
    • 6.2.8. By Region
  • 6.3. Product Market Map

7. Asia-Pacific Pharmacovigilance Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Clinical Trial Phase
    • 7.2.2. By Method
    • 7.2.3. By Service Provider
    • 7.2.4. By Process Flow
    • 7.2.5. By Therapeutic Area
    • 7.2.6. By End-User
    • 7.2.7. By Country
  • 7.3. Asia-Pacific: Country Analysis
    • 7.3.1. China Pharmacovigilance Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Clinical Trial Phase
        • 7.3.1.2.2. By Method
        • 7.3.1.2.3. By Service Provider
        • 7.3.1.2.4. By End-User
    • 7.3.2. India Pharmacovigilance Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Clinical Trial Phase
        • 7.3.2.2.2. By Method
        • 7.3.2.2.3. By Service Provider
        • 7.3.2.2.4. By End-User
    • 7.3.3. Japan Pharmacovigilance Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Clinical Trial Phase
        • 7.3.3.2.2. By Method
        • 7.3.3.2.3. By Service Provider
        • 7.3.3.2.4. By End-User
    • 7.3.4. South Korea Pharmacovigilance Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Clinical Trial Phase
        • 7.3.4.2.2. By Method
        • 7.3.4.2.3. By Service Provider
        • 7.3.4.2.4. By End-User
    • 7.3.5. Australia Pharmacovigilance Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Clinical Trial Phase
        • 7.3.5.2.2. By Method
        • 7.3.5.2.3. By Service Provider
        • 7.3.5.2.4. By End-User

8. Europe Pharmacovigilance Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Clinical Trial Phase
    • 8.2.2. By Method
    • 8.2.3. By Service Provider
    • 8.2.4. By Process Flow
    • 8.2.5. By Therapeutic Area
    • 8.2.6. By End-User
    • 8.2.7. By Country
  • 8.3. Europe: Country Analysis
    • 8.3.1. France Pharmacovigilance Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Clinical Trial Phase
        • 8.3.1.2.2. By Method
        • 8.3.1.2.3. By Service Provider
        • 8.3.1.2.4. By End-User
    • 8.3.2. Germany Pharmacovigilance Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Clinical Trial Phase
        • 8.3.2.2.2. By Method
        • 8.3.2.2.3. By Service Provider
        • 8.3.2.2.4. By End-User
    • 8.3.3. United Kingdom Pharmacovigilance Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Clinical Trial Phase
        • 8.3.3.2.2. By Method
        • 8.3.3.2.3. By Service Provider
        • 8.3.3.2.4. By End-User
    • 8.3.4. Italy Pharmacovigilance Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Clinical Trial Phase
        • 8.3.4.2.2. By Method
        • 8.3.4.2.3. By Service Provider
        • 8.3.4.2.4. By End-User
    • 8.3.5. Spain Pharmacovigilance Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Clinical Trial Phase
        • 8.3.5.2.2. By Method
        • 8.3.5.2.3. By Service Provider
        • 8.3.5.2.4. By End-User

9. North America Pharmacovigilance Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Clinical Trial Phase
    • 9.2.2. By Method
    • 9.2.3. By Service Provider
    • 9.2.4. By Process Flow
    • 9.2.5. By Therapeutic Area
    • 9.2.6. By End-User
    • 9.2.7. By Country
  • 9.3. North America: Country Analysis
    • 9.3.1. United States Pharmacovigilance Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Clinical Trial Phase
        • 9.3.1.2.2. By Method
        • 9.3.1.2.3. By Service Provider
        • 9.3.1.2.4. By End-User
    • 9.3.2. Mexico Pharmacovigilance Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Clinical Trial Phase
        • 9.3.2.2.2. By Method
        • 9.3.2.2.3. By Service Provider
        • 9.3.2.2.4. By End-User
    • 9.3.3. Canada Pharmacovigilance Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Clinical Trial Phase
        • 9.3.3.2.2. By Method
        • 9.3.3.2.3. By Service Provider
        • 9.3.3.2.4. By End-User

10. South America Pharmacovigilance Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Clinical Trial Phase
    • 10.2.2. By Method
    • 10.2.3. By Service Provider
    • 10.2.4. By Process Flow
    • 10.2.5. By Therapeutic Area
    • 10.2.6. By End-User
    • 10.2.7. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pharmacovigilance Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Clinical Trial Phase
        • 10.3.1.2.2. By Method
        • 10.3.1.2.3. By Service Provider
        • 10.3.1.2.4. By End-User
    • 10.3.2. Argentina Pharmacovigilance Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Clinical Trial Phase
        • 10.3.2.2.2. By Method
        • 10.3.2.2.3. By Service Provider
        • 10.3.2.2.4. By End-User
    • 10.3.3. Colombia Pharmacovigilance Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Clinical Trial Phase
        • 10.3.3.2.2. By Method
        • 10.3.3.2.3. By Service Provider
        • 10.3.3.2.4. By End-User

11. Middle East and Africa Pharmacovigilance Market Outlook

  • 11.1. Market Size & Forecast
    • 11.1.1. By Value
  • 11.2. Market Share & Forecast
    • 11.2.1. By Clinical Trial Phase
    • 11.2.2. By Method
    • 11.2.3. By Service Provider
    • 11.2.4. By Process Flow
    • 11.2.5. By Therapeutic Area
    • 11.2.6. By End-User
    • 11.2.7. By Country
  • 11.3. MEA: Country Analysis
    • 11.3.1. South Africa Pharmacovigilance Market Outlook
      • 11.3.1.1. Market Size & Forecast
        • 11.3.1.1.1. By Value
      • 11.3.1.2. Market Share & Forecast
        • 11.3.1.2.1. By Clinical Trial Phase
        • 11.3.1.2.2. By Method
        • 11.3.1.2.3. By Service Provider
        • 11.3.1.2.4. By End-User
    • 11.3.2. Saudi Arabia Pharmacovigilance Market Outlook
      • 11.3.2.1. Market Size & Forecast
        • 11.3.2.1.1. By Value
      • 11.3.2.2. Market Share & Forecast
        • 11.3.2.2.1. By Clinical Trial Phase
        • 11.3.2.2.2. By Method
        • 11.3.2.2.3. By Service Provider
        • 11.3.2.2.4. By End-User
    • 11.3.3. UAE Pharmacovigilance Market Outlook
      • 11.3.3.1. Market Size & Forecast
        • 11.3.3.1.1. By Value
      • 11.3.3.2. Market Share & Forecast
        • 11.3.3.2.1. By Clinical Trial Phase
        • 11.3.3.2.2. By Method
        • 11.3.3.2.3. By Service Provider
        • 11.3.3.2.4. By End-User

12. Market Dynamics

  • 12.1. Drivers
  • 12.2. Challenges

13. Market Trends & Developments

14. Competitive Landscape

  • 14.1. Competition Outlook
  • 14.2. Company Profiles
    • 14.2.1. IBM Corporation
    • 14.2.2. Accenture Plc
    • 14.2.3. Linical Accelovance
    • 14.2.4. Cognizant Technology Solutions Corporation
    • 14.2.5. Laboratory Corporation of America Holdings
    • 14.2.6. ArisGlobal LLC
    • 14.2.7. ICON plc
    • 14.2.8. Capgemini SE
    • 14.2.9. Parexel International Corporation
    • 14.2.10. Wipro Ltd
    • 14.2.11. United BioSource Corporation
    • 14.2.12. BioClinica Inc.
    • 14.2.13. TAKE Solutions Ltd.
    • 14.2.14. ITClinical
    • 14.2.15. Foresight Group International AG

15. Strategic Recommendations

16. About Us & Disclaimer